Ownership and insider activity for Connect Biopharma Holdings Limited (CNTB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody.
Price
| Price | $1.24 |
| Market Cap | $78M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-30 | Xanthopoulos Kleanthis Gabriel | A-Award | 3,738 | |
| 2026-06-30 | LIU JEAN I | A-Award | 6,718 | |
| 2026-05-29 | Huang James | P-Purchase | 150,000 | $372K |
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel | A-Award | 2,816 | |
| 2026-03-31 | LIU JEAN I | A-Award | 5,061 | |
| 2026-03-31 | Huang James | P-Purchase | 1,160,000 | $4.0M |
| 2026-03-18 | Huang James | |||
| 2026-03-16 | Szekeres David Leslie | |||
| 2026-03-16 | Szekeres David Leslie | 1,772,489 | $3.1M | |
| 2026-03-16 | Szekeres David Leslie | 409,355 | $397K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61.3M | $6.4M | $23.7M | $267.7M | $79.0M | $105.7M | $78.2M | $38.3M |
| Short-term Investments | $371012 | $635147 | $306412 | 0 | $73.4M | $12.6M | $15.5M | $6.0M |
| Receivables | 0 | $25109 | $40587 | $7.4M | $232000 | $351000 | $1.1M | $161000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $68.1M | $7.5M | $24.8M | $275.1M | $155.8M | $122.6M | $97.0M | $50.9M |
| Property, Plant & Equipment | $479612 | $70954 | $184485 | $9.4M | $5.4M | $4.7M | $4.2M | $4.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | $8019 | $3.5M | $3.2M | $62000 | $53000 | $45000 |
| Total Assets | $69.3M | $7.7M | $25.4M | $291.1M | $174.0M | $127.4M | $101.3M | $56.1M |
| Accounts Payable | $499672 | $472504 | $577701 | $12.7M | $11.9M | $2.2M | $342000 | $2.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $966556 | $568070 | $890937 | $18.0M | $15.6M | $25.3M | $8.5M | $13.6M |
| Long-term Debt | $87.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $88.7M | $13.9M | $49.5M | $18.8M | $16.5M | $25.9M | $9.1M | $14.1M |
| Retained Earnings | -$18.9M | -$6.1M | -$25.1M | -$361.8M | -$479.8M | -$329.7M | -$345.4M | -$400.8M |
| Total Equity | -$19.4M | -$6.2M | -$24.0M | $272.3M | $157.5M | $101.5M | $92.2M | $42.0M |
| Total Debt | $87.7M | $18287 | $21407 | $125000 | $431000 | $465000 | $178000 | $690000 |
| Net Debt | $21.8M | -$7.0M | -$24.0M | -$267.6M | -$152.0M | -$117.8M | -$93.5M | -$43.7M |
| Working Capital | $67.1M | $7.0M | $23.9M | $257.1M | $140.2M | $97.3M | $88.5M | $37.3M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 3.74 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -5.94 |
Profitability
| Return on Equity | -132.16% |
| Return on Invested Capital | -135.74% |
| Return on Assets | -98.94% |
| Gross Margin | 100.00% |
| Operating Margin | -90740.62% |
| Net Margin | -86687.50% |
Related companies: ARTV · CNTX · IFRX · IMA · KLRS · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of CNTB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks